Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990399 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
A Phase 3 study of Macular Edema Secondary to Inflammation, sponsored by Kodiak Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06990399: Recruiting Phase 3 study of Macular Edema Secondary to Inflammation, sponsored by Kodiak Sciences.
NCT06990399 is a Phase 3 study of Macular Edema Secondary to Inflammation that is actively recruiting participants, run by Kodiak Sciences. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990399, a Phase 3 study of Macular Edema Secondary to Inflammation, is actively recruiting participants, sponsored by Kodiak Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Primary Outcome
Mean change in BCVA from Day 1 to the average of Week 20 and Week 24.
Conditions Studied
Interventions
- OTHER Sham Comparator
- DRUG KSI-101
Study Locations (20)
California
- Global Research Management, Inc. - Glendale
- UCLA Stein Eye Institute - Los Angeles
- Stanford Byers Eye Institute - Palo Alto
- California Eye Specialists Medical Group, Inc. - Pasadena
- California Eye Specialists Medical Group, Inc. - Redlands
- Retina Consultants of Southern California - Redlands
- Retinal Consultants Medical Group Inc - Sacramento
North Carolina
- North Carolina Retina Associates (Cary) - Cary
- North Carolina Retina Associates (Wake Forest) - Wake Forest
Arizona
- Research Network Arizona - Scottsdale
Connecticut
- Retina Group of New England, PC - Waterford
Florida
- Retina Group of Florida (Ft. Lauderdale) - Fort Lauderdale
Indiana
- Associated Vitreoretinal and Uveitis Consultants LLC - Carmel
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Minnesota
- Retina Consultants of Minnesota - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What NCT06990399 shows while recruiting
NCT06990399 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Macular Edema Secondary to Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT06990399 names 20 study sites across 13 states, led by California, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT06990399 about?
NCT06990399 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK". A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
What is the current status of trial NCT06990399?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-07-30. Estimated completion is 2027-07.
What conditions does trial NCT06990399 study?
This clinical trial studies the following conditions: Macular Edema Secondary to Inflammation.
What interventions are being tested in trial NCT06990399?
The interventions under investigation include: Sham Comparator (OTHER), KSI-101 (DRUG).
Who is sponsoring clinical trial NCT06990399?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990399 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema Secondary to Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06990399's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI